Marc Zhang

View mine

[Marc Zhang @mingmingin]

first approved BCG+IO combination

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

FDA approves durvalumab in combination with BCG for high-risk non-muscle invasive #bladdercancer

@IBCG_BladderCA @DrFelixGuerrero @joanfundi @tompowles1 @AndreaNecchi @JoshMeeks #ASCO26

[Marc Zhang @mingmingin]

TaHG as High risk

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Time to revisit something I’ve been saying for years: TaHG bladder cancer is not intermediate risk. The clinical outcomes, molecular biology ... all point in the same direction.

Yet some frameworks allow < 3cm TaHG tumors to be downgraded into “intermediate risk” alongside low-grade disease.

That classification has real consequences for patients:
• undertreatment
• less rigorous surveillance
• in some studies, these patients are even placed on observation as a supposedly appropriate “control arm.”

TaHG is high risk. 🧵 @BladderCancerUS @WorldBladderCan @IBCG_BladderCA

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

A common concern: reduced dose BCG = inferior outcomes.

The data do not support that. Across RCTs and real-world series, 1/3 dose BCG achieves comparable recurrence, progression, and survival outcomes.

Why? BCG is not a fixed-dose drug. Each vial has up to 10-fold variability in viable organisms (CFUs). "Dose" on paper does not reflect true biologic exposure. 🔬

"Full dose" from a low-CFU vial can deliver less BCG than "reduced dose" from a high-CFU vial.

#BladderCancer

[Marc Zhang @mingmingin]

@primemans @grok where the letter

[Marc Zhang @mingmingin]

Wish more patient could preserve their bladder.

[Max Kates @MaxKates]

Great article explaining an important issue. @BladderCancerUS we need advocacy on this issue. @bladd

https://t.co/2ImJ2qacre

[Marc Zhang @mingmingin]

Rapamycin could reverse aging, after being anti-tumor and suppressing immune reactions in renal/other transplants.

[Harshi Peiris, Ph.D. @Neuroscope_mp]

BREAKING:

Scientists gave healthy older adults a transplant drug once a week.

Their immune systems got younger.
Their flu vaccine worked 20% better.
Side effects? Nearly zero.

This is the most exciting anti-aging drug in human history.

Here's what the clinical trials actually show 🧵

[Marc Zhang @mingmingin]

Advance IR patient management and trial design

[Wei Shen Tan @drtanws]

So exciting that this is now in the NCCN guidelines!

No doubt that this will better stratify IR NMIBC patients for clinical trials.

Grateful to @UroDocAsh and the @IBCG_BladderCA team for the opportunity to lead this work

https://t.co/X1QvHxC9HV

[Marc Zhang @mingmingin]

Join and learn the latest update

[Ashish M. Kamat, MD, MBBS @UroDocAsh]

Great initiative by the European Urology team!

A smart way to stay current with the latest across EU journals.

@EurUrolOpen @EurUrolOncol @EurUrolOncol @EUplatinum @Uroweb

[Marc Zhang @mingmingin]

A more common target in Ta intermediate-risk patients.

[Uromigos @Uromigos]

FGFR3 targeted therapy is going though a renaissance with blood based biomarkers, new agents such a Vepugratinib and novel delivery methods (moonrise program) @giannatempopatr @OncoAlert #GUtrendingtopics

[Marc Zhang @mingmingin]

The pembro+EV, PD-1+ADC combination shifts to bladder-sparing.

[Tom Powles @tompowles1]

A 240 pateint single arm trial exploring 9 cycles of EVP without planned surgery in MIBC. This will answer the key questions ‘What happens if we don’t do cystectomy in those with clinical complete response after initial EVP’.It assesses cCR rates and bladder intact EFS. It will clarify ‘EVP 1st ask questions later’ #GUtrendingTopics @OncoAlert

[Sarah P. Psutka MD MS @spsutkaMD]

Thank you @crisbergerot! We are thrilled to be opening the #EMPOWER trial @uwurology @fredhutch *this week* after introducing our protocol at #ASCOGU2026 @HannaHunterMD @CindyLinMD

[Shilpa Gupta @shilpaonc]

#ASCOGU26
Congrats @MattGalsky on leading this novel ph 1 trial of FX-909, a 1st in class oral PPARγ inverse agonist in solid tumors including mUC.

PPARγ is a master regulator of luminal lineage & its activation drives tumorogenesis.
FX-909 shows promising efficacy in IHC selected tumors.
Key TRAEs anemia, hyperglycemia, fatigue. thrombocytopenia.
Provides rationale for dose expansion and combo studies.

Glad to be a part of this novel work.
@CleClinicMD

https://t.co/LZBXU2VK9Z

[UroToday.com @urotoday]

Gemcitabine intravesical system in combination with cetrelimab vs chemoradiotherapy in #MIBC: #SunRISe-2 final results. Presented by @AndreaNecchi @MyUniSR. #GU26 written coverage by @zklaassen_md @GACancerCenter &gt; https://t.co/6QYnF0KN45

[Marc Zhang @mingmingin]

Dr. Andre necchi present Negative SUNrise-2 trial in MIBC bladder sparing with no chemo scheme.

[Marc Zhang @mingmingin]

Robert speak on SWOG S1602 BCG strain TICE https://t.co/E02AyMFKoO.

[Marc Zhang @mingmingin]

Dr.Noah hahn For and Dr. Felix GR Against BCG+IO in BCG naive NMIBC，continue discussion from ESMO last year in several session.

[Marc Zhang @mingmingin]

KEYNOTE-B15 trial move MIBC to no cisplatin era after la/m BC. more 👏🏻👏🏻👏🏻interrupt Dr.Galsky presentation. #ASCOGU26

[David K. Yang @davidkmyang]

Nice progress on drugging p53. It’s true that we need to find new targets, but it’s also important to keep expanding the druggable universe with better technologies.

Lots of great targets we already know about that are just waiting for the right molecule

[LARVOL @Larvol]

With ASCO GU 2026 upon us, oncologists are already weighing in, sharing, and debating the most anticipated genitourinary oncology abstracts ahead of the meeting.

We’re tracking these conversations in real time and analyzing what’s gaining traction across the community. Here are the pre-conference Top abstracts for ASCO GU 2026.

Special thanks to Dr. Mike Thompson (@mtmdphd) for the original idea.

Which abstract are you watching at American Society of Clinical Oncology (@ASCO) Genitourinary Cancers Symposium 2026?

Explore more insights and data from #GU26: https://t.co/hJxifSvzwe

#LARVOL #ASCOGU26 #CancerResearch #CancerData #Oncology #OncologyInsights #GUCancer #GenitourinaryCancer #GUCSM

Discussion threads:

Dr. Álvaro Pinto (@dralvaropinto): https://t.co/QzcyAcXVNc

Dr. Amol Akhade (@SuyogCancer): https://t.co/wpcQH6ZSVs

Dr. Karine Tawagi (@DrKarineTawagi): https://t.co/TEhBOdZhGQ

Dr. Mustafa J. Saleh (@Mustafajsalehmd): https://t.co/Y82NahkRkO

Dr. Tom Powles (@tompowles1): https://t.co/F1r3vN8U1i

Dr. Toni Choueiri (@DrChoueiri): https://t.co/opgp6JAJoL